Some FLT3 kinase inhibitors such as MRX-2843, UNC 2025, Giltertinib, and ONO-7475 are dual kinase inhibitors that inhibit TAM (TYRO, AXL, MER) receptor tyrosine kinase (RTK) in non-small cell lung cancer (NSCLC) and breast cancer (Zhang et al., 2014; Minson et al., 2016; Mori et al., 2017; Wu et al., 2018b; Okura et al., 2020). The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.